N/A
N=553
Characteristics of Sexual Dysfunction in Patients With Lung Cancer
Lung Cancer · Sexual Dysfunction
Bottom Line
View on ClinicalTrials.gov: NCT06018376 ↗Enrolled (actual)
553
Serious AEs
—
Results posted
Feb 2026
Primary outcome: Primary: Number of Participants With Different Type, Frequency and Severity of Sexual Dysfunction — 71; 275; 76; 51 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Systemic oncological treatment (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Fundación GECP
- Primary completion
- Feb 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Different Type, Frequency and Severity of Sexual Dysfunction |
71; 275; 76; 51; 70; 71 | — |
Summary
The general objective of this observational study is identify and describe the type, frequency, and severity of sexual dysfunction in patients with lung cancer and generate strategies for clinical management and oncological follow-up directed and based on the specific findings in this population. The recruitment will be carried out from July 2023 and will be carried out until December 2023, the analysis of the information will be carried out from January to March 2024.
Eligibility Criteria
Inclusion Criteria
- Age greater than or equal to 18 years and less than or equal to 70 years.
- Diagnosis of lung cancer stages IB to IV.
- Having received systemic oncological treatment for at least 3 months or being in oncological follow-up after having received systemic treatment for a minimum of 3 months with stable tumor disease or partial or complete response in images.
- ECOG ≤ 2
Exclusion Criteria
- Patients with comorbidities (renal failure, cardiovascular diseases or similar) not controlled with corresponding medical management.
- Individuals with physical disability or cognitive impairment that prevents them from completing the electronic data collection form.
Data sourced from ClinicalTrials.gov (NCT06018376). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.